Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT05035407 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2025-12-02 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Site plans to become a site for a multicenter study of this therapy” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-09Also stopped (terminated): Alaunos Therapeutics, Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) (NCT05194735)
- 2026-05-15Also stopped (terminated): Iovance Biotherapeutics, Inc., Lifileucel + LN-145 (NCT03645928)
- 2026-02-23Also stopped (withdrawn): Intima Bioscience, Inc., Fludarabine + Cyclophosphamide (NCT05566223)
- 2025-11-10Results posted on the registry: Alaunos Therapeutics, Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) (NCT05194735)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision